TrialPloS one2024

Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.

Jens Panse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.